223 related articles for article (PubMed ID: 20153385)
41. Physicochemical characterization, cytotoxic effect and toxicity evaluation of nanostructured lipid carrier loaded with eucalyptol.
Izham MNM; Hussin Y; Rahim NFC; Aziz MNM; Yeap SK; Rahman HS; Masarudin MJ; Mohamad NE; Abdullah R; Alitheen NB
BMC Complement Med Ther; 2021 Oct; 21(1):254. PubMed ID: 34620132
[TBL] [Abstract][Full Text] [Related]
42. Size-exclusive effect of nanostructured lipid carriers on oral drug delivery.
Li H; Chen M; Su Z; Sun M; Ping Q
Int J Pharm; 2016 Sep; 511(1):524-537. PubMed ID: 27452421
[TBL] [Abstract][Full Text] [Related]
43. PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization.
Nasr M; Najlah M; D'Emanuele A; Elhissi A
Int J Pharm; 2014 Jan; 461(1-2):242-50. PubMed ID: 24275446
[TBL] [Abstract][Full Text] [Related]
44. Design and characterization of Nanostructured lipid carriers (NLC) and Nanostructured lipid carrier-based hydrogels containing Passiflora edulis seeds oil.
Krambeck K; Silva V; Silva R; Fernandes C; Cagide F; Borges F; Santos D; Otero-Espinar F; Lobo JMS; Amaral MH
Int J Pharm; 2021 May; 600():120444. PubMed ID: 33713760
[TBL] [Abstract][Full Text] [Related]
45. In situ intestinal permeability and in vivo oral bioavailability of celecoxib in supersaturating self-emulsifying drug delivery system.
Song WH; Yeom DW; Lee DH; Lee KM; Yoo HJ; Chae BR; Song SH; Choi YW
Arch Pharm Res; 2014 May; 37(5):626-35. PubMed ID: 23852645
[TBL] [Abstract][Full Text] [Related]
46. A novel oral delivery system consisting in "drug-in cyclodextrin-in nanostructured lipid carriers" for poorly water-soluble drug: vinpocetine.
Lin C; Chen F; Ye T; Zhang L; Zhang W; Liu D; Xiong W; Yang X; Pan W
Int J Pharm; 2014 Apr; 465(1-2):90-6. PubMed ID: 24530388
[TBL] [Abstract][Full Text] [Related]
47. Nanostructured lipid carriers as novel drug delivery system for lung cancer gene therapy.
Han Y; Li Y; Zhang P; Sun J; Li X; Sun X; Kong F
Pharm Dev Technol; 2016; 21(3):277-81. PubMed ID: 25560648
[TBL] [Abstract][Full Text] [Related]
48. Beclomethasone-loaded lipidic nanocarriers for pulmonary drug delivery: preparation, characterization and in vitro drug release.
Jaafar-Maalej C; Andrieu V; Elaissari A; Fessi H
J Nanosci Nanotechnol; 2011 Mar; 11(3):1841-51. PubMed ID: 21449319
[TBL] [Abstract][Full Text] [Related]
49. Nanostructured lipid carrier (NLC) based gel of celecoxib.
Joshi M; Patravale V
Int J Pharm; 2008 Jan; 346(1-2):124-32. PubMed ID: 17651933
[TBL] [Abstract][Full Text] [Related]
50. Nanostructured lipid carriers for site-specific drug delivery.
Khosa A; Reddi S; Saha RN
Biomed Pharmacother; 2018 Jul; 103():598-613. PubMed ID: 29677547
[TBL] [Abstract][Full Text] [Related]
51. Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application.
Pardeike J; Weber S; Haber T; Wagner J; Zarfl HP; Plank H; Zimmer A
Int J Pharm; 2011 Oct; 419(1-2):329-38. PubMed ID: 21839157
[TBL] [Abstract][Full Text] [Related]
52. DoE-based development of celecoxib loaded PLGA nanoparticles: In ovo assessment of its antiangiogenic effect.
Alonso-González M; Fernández-Carballido A; Quispe-Chauca P; Lozza I; Martín-Sabroso C; Isabel Fraguas-Sánchez A
Eur J Pharm Biopharm; 2022 Nov; 180():149-160. PubMed ID: 36220520
[TBL] [Abstract][Full Text] [Related]
53. Development, characterization and evaluation of doxorubicin nanostructured lipid carriers for prostate cancer.
Zhang HW; Dang Q; Zhang ZW; Wu FS
J BUON; 2017; 22(1):102-111. PubMed ID: 28365942
[TBL] [Abstract][Full Text] [Related]
54. Agranulocytosis-Protective Olanzapine-Loaded Nanostructured Lipid Carriers Engineered for CNS Delivery: Optimization and Hematological Toxicity Studies.
Gadhave DG; Tagalpallewar AA; Kokare CR
AAPS PharmSciTech; 2019 Jan; 20(1):22. PubMed ID: 30604305
[TBL] [Abstract][Full Text] [Related]
55. Enhanced Pharmacokinetic Activity of Zotepine via Nanostructured Lipid Carrier System in Wistar Rats for Oral Application.
Tirumalesh C; Suram D; Dudhipala N; Banala N
Pharm Nanotechnol; 2020; 8(2):148-160. PubMed ID: 32096755
[TBL] [Abstract][Full Text] [Related]
56. Ethyl oleate-containing nanostructured lipid carriers improve oral bioavailability of trans-ferulic acid ascompared with conventional solid lipid nanoparticles.
Zhang Y; Li Z; Zhang K; Yang G; Wang Z; Zhao J; Hu R; Feng N
Int J Pharm; 2016 Sep; 511(1):57-64. PubMed ID: 27374194
[TBL] [Abstract][Full Text] [Related]
57. Photo-responsive and NGR-mediated multifunctional nanostructured lipid carrier for tumor-specific therapy.
Yang Y; Xie X; Yang Y; Zhang H; Mei X
J Pharm Sci; 2015 Apr; 104(4):1328-39. PubMed ID: 25630979
[TBL] [Abstract][Full Text] [Related]
58. Preparation of Coenzyme Q10 nanostructured lipid carriers for epidermal targeting with high-pressure microfluidics technique.
Chen S; Liu W; Wan J; Cheng X; Gu C; Zhou H; Chen S; Zhao X; Tang Y; Yang X
Drug Dev Ind Pharm; 2013 Jan; 39(1):20-8. PubMed ID: 23116283
[TBL] [Abstract][Full Text] [Related]
59. Quality by design (QbD) optimization of diazepam-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery: Toxicological effect of surface charge on human neuronal cells.
Costa CP; Cunha S; Moreira JN; Silva R; Gil-Martins E; Silva V; Azevedo L; Peixoto AF; Sousa Lobo JM; Silva AC
Int J Pharm; 2021 Sep; 607():120933. PubMed ID: 34324988
[TBL] [Abstract][Full Text] [Related]
60. Development of nanostructured lipid carriers containing salicyclic acid for dermal use based on the Quality by Design method.
Kovács A; Berkó S; Csányi E; Csóka I
Eur J Pharm Sci; 2017 Mar; 99():246-257. PubMed ID: 28012940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
